Objective: Genomewide association studies have consistently found variants in fibroblast growth factor receptor 2 (FGFR2) to be associated with breast cancer. Recent reports suggest that postmenopausal hormone therapy (HT) use may modify the association between single nucleotide polymorphisms (SNPs) in FGFR2 and breast cancer risk. We assessed the hypothesis that the association between rs1219648 (FGFR2) SNP and breast cancer risk is modified by postmenopausal HT use in a population-based case-control study.
F ibroblast growth factor receptor 2 (FGFR2) has been linked to breast cancer incidence in a variety of ways. FGFR2 codes for a protein expressed in breast tumors 1 and, most notably, single nucleotide polymorphisms (SNPs) in the gene have been associated with breast cancer risk in genomewide association studies. 2<4 rs1219648 in intron 2 was the SNP most significantly associated with breast cancer risk in a two-stage genomewide association study conducted by Hunter et al. 2 Women homozygous for the risk allele had a 64% increase in breast cancer risk in comparison with women with wild-type alleles. A haplotype block encompassing the same region of FGFR2 has been shown to affect gene expression, which may explain the link to breast cancer risk. 5 Evidence suggests that FGFR2 is more strongly associated with hormonally related breast cancer. 6<8 In a study using pooled data from the Breast Cancer Association Consortium, the association between FGFR2 and breast cancer incidence was stronger in women diagnosed with estrogen receptor positive and progesterone receptor positive breast cancers than in women with hormone receptor negative tumors. 8 Most recently, gene-environment interactions between FGFR2 and postmenopausal hormone therapy (HT) have been reported to increase breast cancer risk in some, 9, 10 but not all, investigations. 11 Rebbeck et al 9 observed an odds ratio (OR) for breast cancer of 2.63 (95% confidence interval [CI], 1.46-4.76) for estrogen plus progestogen HT use and homozygosity for the major allele, whereas estrogen plus progestogen hormone use and heterozygosity had an OR of 0.49 (95% CI, 0.26-0.95). The association between breast cancer risk and rs3750817 (another SNP in intron 2 that is not in linkage disequilibrium with rs1219648) was modified by the type of HT formulation. In the large, prospective Women's Health Initiative, Prentice et al 10 found that when compared with never users who were homozygous for the minor allele, estrogen HT users had a decreased risk of disease with an OR of 0.34 (95% CI, 0.15-0.76), whereas estrogen plus progestogen therapy users had an OR of 0.69 (95% CI, 0.41-1.17). We examined the association between FGFR2 rs1219648 genotype, HT use, and breast cancer risk in a population-based case-control study.
METHODS

Study population
Data from a previously described population-based casecontrol study were used for this study. 12, 13 Eligible participants were selected from population lists of English-speaking women residing in Massachusetts (excluding metropolitan Boston), New Hampshire, or Wisconsin. Cases included in the analysis were postmenopausal women aged 36 to 75 years with an incident invasive breast cancer reported to state cancer registries between 1995 and 2000. Community controls were randomly selected in each state from population lists of licensed drivers (if younger than 65 y) and lists of Medicare beneficiaries (if aged 65 y or older). Controls were frequency matched to approximate the age distribution of the cases within 5-year age strata. This study was conducted with approval from the Institutional Review Boards at Dartmouth Medical School, Harvard University, University of Wisconsin-Madison, and the National Cancer Institute.
Risk factor information
Telephone interviews were used to obtain information on demographics, family history of cancer, reproductive exposures, and use of exogenous hormones. Detailed information on HT usage patterns, type of formulation, and duration of use was acquired. Participant interviews were conducted, on average, 1 year after a specified reference date. The reference date for each participant was defined as the date of cancer diagnosis for cases and as a comparable date for control participants, based on their 5-year age strata and interview date. Among eligible participants, approximately 80% of cases and 76% of controls completed the interview.
Genotyping
Participants were asked to donate a buccal cell sample for genetic analyses. Samples were sent by mail to a National Cancer InstituteYaffiliated laboratory for processing. DNA collection, isolation, and storage were conducted according to previously described protocols. 12 Whole genome amplification using multiple displacement amplification was performed at Vanderbilt University according to the manufacturer's instructions (Qiagen, Valencia, CA) to increase the amount of genomic DNA. Genotyping was conducted at the Survey and Biospecimen Shared Resource, Vanderbilt University, using the TaqMan (5 ¶-nuclease assay) genotyping assay in ABI PRISM 7900 Sequence Detection Systems (Applied Biosystems). Seventy percent of interviewed cases and 61% of interviewed controls agreed to donate a genetic sample. To reduce the possibility of population stratification, we limited all analyses to participants self-identified as white (97.3% of postmenopausal participants).
Statistical analyses
Our analysis included white postmenopausal women who returned a DNA sample for a total of 869 cases and 808 controls. Participants were considered postmenopausal if they reported that their menstrual cycles had stopped for at least the last 6 months before the reference date. Hardy-Weinberg equilibrium was tested in controls by comparing observed genotype frequencies to expected genotype frequencies. Logistic regression was used to calculate ORs and 95% CIs for the association between breast cancer and FGFR2 rs1219648 genotype, as well as associations with established breast cancer risk factors. Under an additive genetic model, dummy variables were used to model heterozygote and minor allele homozygote associations for rs1219648. All statistical models included terms for age and state of residence. ORs were further adjusted for the following potential confounding variables: age at menarche, parity, age at first birth, ever smoking status, diabetes diagnosis, and body mass index (kg/m 2 ) 1 year before diagnosis. The association between rs1219648 and breast cancer risk showed little evidence of confounding by established breast cancer risk factors; consequently, results are displayed from age-and state-adjusted models. A statistical test for the trend in breast cancer risk by the number of minor alleles present was calculated by including an ordinal term in the regression.
Potential interactions were evaluated by including crossproduct terms combining recency, duration, or ever use of HT with the number of minor rs1219648 alleles in multivariate models. Ever use of HT was defined as consecutive use of postmenopausal hormones of any kind for at least 1 month. Results of analyses where ever use was defined as three or more months were similar to the presented results. The HT variable was then dichotomized based on formulation type as users of estrogen-only medications or users of estrogen plus progestogen therapy, which included participants who had ever taken medications containing a progestogen component (combined estrogen plus progestogen ever users, N = 484; progestogen-only ever users, N = 16). Results were similar for the estrogen plus progestogen therapy group in analyses that did and did not include progestogen-only users. Participants taking other types of hormone formulations (N = 38) were not included in subgroup analyses. HT duration was defined in approximate tertiles of use as less than 5, 5 to 9, and 10 or more years. Current HT use was defined as use within the calendar year 2 years prior to the reference date. This variable was defined as such to permit time for HT to affect breast cancer risk.
To elucidate whether risks differ by HT usage patterns, interactions were explored between genotype and HT use by calculating ORs for the association between rs1219648 and breast cancer risk stratified by HT ever use, formulation, or current use. In analyses accounting for HT use, participants homozygous for the major allele (AA) and who had not used HT were treated as the reference group.
RESULTS
Selected genetic and HT usage characteristics are presented in Table 1 . Study participants who chose not to provide a DNA sample for genetic analyses tended to be younger than individuals who provided a sample, but were similar in other established risk factors for breast cancer. 14 In this study, breast cancer cases tended to have a later age at menopause and were more likely to have a family history of the disease than controls. Estrogen plus progestogen therapy users had an increased risk of breast cancer compared with never users of HT (OR, 1.31; 95% CI, 1.03-1.66). Current and long-term (Q10 y) hormone users of any formulation had an increased risk of breast cancer. There was no significant departure from Hardy-Weinberg equilibrium in allelic frequencies for rs1219648 among the controls (P = 0.27). Women with one or more copies of the minor allele for rs1219648 had an increased risk of breast cancer when compared with women with both wild-type alleles (AA), with a per-allele risk increase of 22% (95% CI, 6%-41%). We observed that ever users of HT with at least one copy of the G allele of rs1219648 had an increased risk of breast cancer when compared with never users homozygous for the major allele (Table 2 ). Ever users with AG genotype had an OR of 1.38 (95% CI, 1.01-1.90), and ever users with GG genotype had an elevated OR of 1.68 (95% CI, 1.08-2.62). Although not statistically significant, the point estimates for never users with one or more copies of the minor allele were in the same direction as ever users (AG genotype: OR, 1.28; 95% CI, 0.92-1.78; GG genotype: OR, 1.26; 95% CI, 0.81-1.98). The observed risk associated with the rs1219648 minor allele genotype did not differ significantly by the type of HT used, although excess risk among minor allele homozygotes was more prominent in estrogen therapy users (OR, 1.93; 95% CI, 1.11-3.36) than in those who used estrogen plus progestogen therapy (OR, 1.25; 95% CI, 0.69-2.25). Moreover, there was evidence of an interaction among ever users of estrogenonly HT and the risk allele of rs1219648 to increase breast cancer risk (interaction P = 0.08), but the interaction between rs1219648 minor alleles and estrogen plus progestogen therapy was not evident (interaction P = 0.48).
Current users with at least one copy of the risk allele had an increased breast cancer risk when compared with never users with AA genotype ( Table 2) . Current ever users with GG genotype had a 69% increased risk of breast cancer compared with wild-type never users. There was suggestive, but not statistically significant, evidence for an interaction between current estrogen HT and increasing number of rs1219648 minor alleles (P = 0.10). Current estrogen plus progestogen therapy use did not modify the association between the FGFR2 variant and breast cancer risk (P = 0.60). Overall, estrogen plus progestogen therapy users had an elevated risk of breast cancer in comparison with never users with AA genotype. Tests for interaction between duration of HT and genotype were null (P = 0.55) irrespective of formulation type.
DISCUSSION
Consistent with previous reports focused on this region of FGFR2, 2<4,6,15,16 we found an increased risk of breast cancer with increasing number of risk alleles for FGFR2 rs1219648. We also assessed whether the relationship between rs1219648 and invasive breast cancer risk was modified by HT use in a population-based sample, as previous studies have reported a difference in the effect that SNPs in FGFR2 exhibit on breast cancer risk according to HT use. 9, 10 Variants in FGFR2 are hypothesized to act through hormonal pathways to influence breast cancer risk because of the variants' stronger association with hormone receptorYpositive tumors. 8 In a study involving 1,225 participants, Rebbeck et al 9 reported a significant interaction between the use of estrogen plus progestogen therapy and rs1219648 in breast cancer risk (P = 0.01). Estrogen plus progestogen therapy users who were wild type at this locus were at an increased risk of disease compared with never users with the same genotype (OR, 2.63; 95% CI, 1.46-4.76). Our study found a weaker effect with an OR of 1.31 (95% CI, 0.87-1.97). Rebbeck et al 9 did not assess whether estrogen-only formulations modified the association between FGFR2 and breast cancer risk. In a separate study, the Women's Health Initiative did not find evidence of interaction between the type of HT formulation used and rs1219648 genotype. The Women's Health Initiative observed no difference in breast cancer risk associated with the minor allele of rs1219648 in either the estrogen therapy arm (P = 0.42) or the estrogen plus progestin therapy arm (P = 0.66) of the randomized trial. 10 We observed suggestive, but not statistically significant, evidence of an interaction with current estrogen therapy use but did not detect an interaction between FGFR2 and current estrogen plus progestogen therapy use. Recently, the Million Women Study explored interactions between current HT use and rs2981582, a SNP located in FGFR2 that is in strong linkage disequilibrium with rs1219648. The investigators found no evidence of difference in the increased breast cancer risk associated with the minor allele of rs2981582 by current HT use or HT formulation. 11 Analysis restricted to cases diagnosed with estrogen receptorYpositive disease also did not support an interaction between FGFR2 and current HT use. Our study and the Million Women Study both found little evidence of an interaction between current HT use and FGFR2 SNPs; in addition, we also evaluated whether the duration of HT use modified the effect of FGFR2 genotype on breast cancer risk and found no evidence of heterogeneity in risk by duration of HT use.
The strength of the current study was the use of comprehensive interview data on HT usage patterns, duration, and type of formulation to evaluate interactions. We believe that recall bias is unlikely to play a role in our findings, as genotype assessment is not subject to this type of error. However, breast cancer cases may suspect that their diagnosis was related to previous HT use and be more thoughtful in answering questions about their HT usage patterns than controls which could lead to recall bias. We assert that the categorization of HT use into never use versus ever use has been reliably answered and is less susceptible to bias than more specific HT questions. HT formulation may be harder to recall; this error would most probably be nondifferential, potentially diluting the association toward the null.
A limitation of the study, however, was our lack of information on hormone receptor status. Most, 1, 6, 8, 17 but not all, 11 studies have suggested stronger associations between FGFR2 and estrogen receptor positive tumors. Although most diagnosed breast cancers are estrogen receptor positive, 18 our findings may be attenuated toward the null by including estrogen receptorY negative tumors in the analyses. Our results are expected to be generalizable to similar populations of postmenopausal women throughout the United States. The association between rs1219648 and breast cancer risk is not likely to vary if the SNP is present in the population. We found evidence that estrogenonly HT may modify the association between FGFR2 and breast cancer risk, yet replication of this finding in larger studies is needed.
CONCLUSIONS
In summary, these data suggest that the association of rs1219648 with breast cancer risk does not seem to be strongly influenced by HT use or duration of HT. The study raises the possibility that the FGFR2 rs1219648 variant is more strongly associated with risk in estrogen therapy users, although this observation needs to be examined in larger studies.
